Americans are microdosing obesity drugs, driven by ‘thin is in’ marketing blitz

·

·

Doctors warn that microdosing copycat Ozempic and other GLP-1s is not approved for people with low BMIs and carries risks of serious side effects like pancreatic damage.



Leave a Reply

Your email address will not be published. Required fields are marked *